Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
Status:
Completed
Trial end date:
2019-07-17
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study to evaluate the effect of
tenapanor on change in s-P levels when tenapanor is administered orally, twice daily for 28
days as adjunctive therapy to ESRD subjects with hyperphosphatemia on stable phosphate binder
therapy.